Skip to main content
. 2015 Jul 31;7(5):829–837. doi: 10.1080/19420862.2015.1060384

Figure 5.

Figure 5.

Predictions of PK- binding model based on a typical pulmonary fibrosis patient. Once-a-week intravenous infusions of QBP359 (3 mg kg−1, 6 mg kg−1, 10 mg kg−1, 20 mg kg−1 and 50 mg kg−1) were applied to the model. Simulations of total QBP359 in serum (top left), total CCL21 (top right),% free CCL21 in serum (bottom left) and % free CCL21 in peripheral tissue (bottom right) are shown.